Laboratory Corporation of America Holdings (LH) Income Statement

NYSE: LHRevenue, profits, margins and EPS over 10 years.

LH 2025 at a glance

Fiscal year ended December 31, 2025 · U.S. dollars
Revenue+7.2%
$13.95B
2025 · hover or tap a bar for each year
2016: $9.64B (+11.1%)2017: $10.44B (+8.3%)2018: $11.33B (+8.5%)2019: $11.55B (+2.0%)2020: $13.98B (+21.0%)2021: $13.14B (−6.0%)2022: $11.86B (−9.7%)2023: $12.16B (+2.5%)2024: $13.01B (+7.0%)2025: $13.95B (+7.2%)
20162025
Gross profit+3.0%
$3.73B
2025 · hover or tap a bar for each year
2016: $3.18B (+9.5%)2017: $3.46B (+8.9%)2018: $3.18B (−8.3%)2019: $3.25B (+2.4%)2020: $4.95B (+52.3%)2021: $4.99B (+0.8%)2022: $3.71B (−25.7%)2023: $3.36B (−9.3%)2024: $3.62B (+7.7%)2025: $3.73B (+3.0%)
20162025
Operating income+39.5%
$1.52B
2025 · hover or tap a bar for each year
2016: $1.31B (+30.9%)2017: $1.36B (+3.9%)2018: $1.33B (−2.8%)2019: $1.33B (+0.3%)2020: $2.45B (+83.8%)2021: $3.05B (+24.7%)2022: $1.44B (−52.9%)2023: $725.6M (−49.5%)2024: $1.09B (+49.8%)2025: $1.52B (+39.5%)
20162025
Net income+17.5%
$876.5M
2025 · hover or tap a bar for each year
2016: $732.1M (+67.6%)2017: $1.27B (+73.2%)2018: $883.7M (−30.3%)2019: $823.8M (−6.8%)2020: $1.56B (+88.9%)2021: $2.38B (+52.8%)2022: $1.28B (−46.2%)2023: $418.0M (−67.3%)2024: $746.0M (+78.5%)2025: $876.5M (+17.5%)
20162025
EPS (diluted)+12.8%
$16.44
2025 · hover or tap a bar for each year
2016: $8.73 (+10.9%)2017: $9.60 (+10.0%)2018: $11.02 (+14.8%)2019: $11.31 (+2.6%)2020: $23.91 (+111.4%)2021: $28.51 (+19.2%)2022: $19.89 (−30.2%)2023: $13.92 (−30.0%)2024: $14.57 (+4.7%)2025: $16.44 (+12.8%)
20162025
Net profit margin+0.5 pts
6.3%
2025 · hover or tap a point for each year
2016: 7.6% (+2.6 pts)2017: 12.1% (+4.6 pts)2018: 7.8% (−4.3 pts)2019: 7.1% (−0.7 pts)2020: 11.1% (+4.0 pts)2021: 18.1% (+7.0 pts)2022: 10.8% (−7.3 pts)2023: 3.4% (−7.3 pts)2024: 5.7% (+2.3 pts)2025: 6.3% (+0.5 pts)
20162025

LH revenue and net income

RevenueNet incomeNet margin (right axis)

Where LH's revenue goes

2025
Revenue
$13.95B100.0%
Cost of revenue
−$10.22B−73.2%
Gross profit
$3.73B26.8%
Sales, general & admin
−$2.22B−15.9%
Operating income
$1.52B10.9%
Interest & other expense
−$408.7M−2.9%
Income taxes
−$229.8M−1.6%
Net income
$876.5M6.3%

Each bar shows an amount and its share of revenue. LH kept 6.3% of revenue as net income.

LH profit margins

GrossOperatingNet

LH growth rates

to 2025
1 year3 years5 years10 years
Revenue+7.2%+5.6%−0.0%+4.9%
Gross profit+3.0%+0.2%−5.5%+2.5%
Operating income+39.5%+1.8%−9.1%+4.2%
Net income+17.5%−11.8%−10.8%+7.2%
EPS (diluted)+12.8%−6.2%−7.2%+7.6%

1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.

LH quarterly EPS vs estimates

Reported EPSAnalyst estimate

Labcorp beat the analyst EPS estimate in 8 of the last 8 quarters. Next report: October 28, 2026 (estimate $4.65).

LH income statement

Laboratory Corporation of America Holdings annual income statement
2025202420232022202120202019201820172016
Revenue$13.95B$13.01B$12.16B$11.86B$13.14B$13.98B$11.55B$11.33B$10.44B$9.64B
Cost of revenue$10.22B$9.38B$8.80B$8.15B$8.14B$9.03B$8.30B$8.16B$6.98B$6.46B
Gross profit$3.73B$3.62B$3.36B$3.71B$4.99B$4.95B$3.25B$3.18B$3.46B$3.18B
Research & development——$2.0M————$0$0$0
Sales, general & admin$2.22B$2.23B$2.18B$2.00B$1.95B$1.73B$1.62B$1.57B$1.81B$1.63B
Total operating expenses$2.22B$2.54B$2.64B$2.27B$1.94B$2.51B$1.87B$1.80B$2.03B$1.81B
Operating income$1.52B$1.09B$725.6M$1.44B$3.05B$2.45B$1.33B$1.33B$1.36B$1.31B
Interest income$222.2M$202.7M$172.2M$166.0M$175.4M$194.2M$212.3M$225.1M$221.7M$209.5M
Interest expense$224.1M$208.3M$199.6M$179.8M$211.8M$207.4M$240.7M$244.2M$235.1M$219.1M
Income before taxes$1.11B$959.5M$568.9M$1.24B$2.89B$2.22B$1.10B$1.27B$1.13B$1.11B
Income taxes$229.8M$212.4M$188.5M$233.9M$690.0M$662.1M$280.0M$384.4M−$139.1M$372.3M
Net income$876.5M$746.0M$418.0M$1.28B$2.38B$1.56B$823.8M$883.7M$1.27B$732.1M
EBITDA$2.01B$1.81B$1.35B$1.95B$3.68B$3.05B$1.92B$2.06B$1.85B$1.82B
EPS (diluted)$16.44$14.57$13.92$19.89$28.51$23.91$11.31$11.02$9.60$8.73
Gross margin26.8%27.9%27.7%31.3%38.0%35.4%28.1%28.0%33.2%33.0%
Operating margin10.9%8.4%6.0%12.1%23.2%17.5%11.5%11.7%13.1%13.6%
Net margin6.3%5.7%3.4%10.8%18.1%11.1%7.1%7.8%12.1%7.6%

Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in LH's financial statements (latest annual report filed February 24, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.

LH financial results

In fiscal year 2025 (ended December 31, 2025), Labcorp reported revenue of $14.0 billion, up 7.2% from the year before. It had net income of $876.5 million (up 17.5%), a net profit margin of 6.3%. Diluted earnings per share came to $16.44. Over five years revenue grew at an average rate of −0.0% a year.

See the LH stock overview for the latest quote and news, or the LH chart for price history and technical indicators.

LH income statement FAQ

What is Labcorp's annual revenue?

Labcorp reported total revenue of $14.0 billion for fiscal year 2025, which ended on December 31, 2025. That was up 7.2% from $13.0 billion the previous year.

Is Labcorp profitable?

Yes. Labcorp reported net income of $876.5 million in fiscal 2025, a net profit margin of 6.3%; its operating margin was 10.9%.

What is Labcorp's gross margin?

Labcorp's gross margin was 26.8% in fiscal 2025: for every $100 of revenue, Labcorp kept $27 after the direct cost of its products and services.

How fast is Labcorp growing?

Revenue grew −0.0% a year on average over the last five fiscal years, from $14.0 billion to $14.0 billion.

What are Labcorp's earnings per share?

Labcorp earned $16.44 per diluted share in fiscal 2025, compared with $14.57 a year earlier.

When will Labcorp report its next earnings?

Labcorp is expected to report results for the quarter ending September 30, 2026 on October 28, 2026 before the market opens.

When does Labcorp's fiscal year end?

Labcorp's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on February 24, 2026.

Diagnostics & Research income statements